A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04566770

Recruitment Status : Recruiting

First Posted : September 28, 2020

Last Update Posted : November 27, 2020

See Contacts and Locations

Sponsor:

Collaborators:

Beijing Institute of Biotechnology

Jiangsu Province Centers for Disease Control and Prevention

Information provided by (Responsible Party):

CanSino Biologics Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	August 21, 2021
Estimated Study Completion Date :	October 20, 2022

To Top